MIYAJI; Hiromasa

Patent Applications and Registrations

Patent applications and USPTO patent grants for MIYAJI; Hiromasa.The latest application filed is for "cell population with enhanced transplantation activity".

Company Profile

0.13.11

MIYAJI; Hiromasa - Machida-shi JP
Miyaji; Hiromasa - Sunto-gun JP
Miyaji; Hiromasa - Tokyo JP
Miyaji; Hiromasa - Setagaya-ku JP

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cell Population With Enhanced Transplantation Activity App 20100303766 - MIYAJI; Hiromasa ; et al.	2010-12-02
Polypeptides Having Phospholipase A2 Activity App 20080044425 - Miyaji; Hiromasa ; et al.	2008-02-21
Polypeptides having phospholipase A.sub.2 activity Grant 7,258,855 - Miyaji , et al. August 21, 2	2007-08-21
Process for producing humanized chimera antibody App 20070073043 - Shitara; Kenya ; et al.	2007-03-29
Preventive and/or trerapeutic drgs for itch App 20060252679 - Saki; Mayumi ; et al.	2006-11-09
Preventive and/or therapeutic drugs for asthma App 20060239999 - Saki; Mayumi ; et al.	2006-10-26
Phosphodiesterase inhibitor App 20060111368 - Osakada; Naoto ; et al.	2006-05-25
Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3 Grant 7,045,129 - Shitara , et al. May 16, 2	2006-05-16
Process for producing humanized chimera antibody App 20060058512 - Shitara; Kenya ; et al.	2006-03-16
Process for producing humanized chimera antibody App 20060057139 - Shitara; Kenya ; et al.	2006-03-16
Process for producing humanized chimera antibody Grant 6,965,024 - Shitara , et al. November 15, 2	2005-11-15
Polypeptides having phospholipase a2 activity App 20040014089 - Miyaji, Hiromasa ; et al.	2004-01-22
Process for producing humanized chimera antibody App 20030095964 - Shitara, Kenya ; et al.	2003-05-22
Human chimeric antibody specific for the ganglioside GD3 Grant 6,437,098 - Shitara , et al. August 20, 2	2002-08-20
Process for producing humanized chimera antibody App 20020026036 - Shitara, Kenya ; et al.	2002-02-28
G-CSF conjugate Grant 6,027,720 - Kuga , et al. February 22, 2	2000-02-22
Process for producing humanized chimera antibody Grant 5,866,692 - Shitara , et al. February 2, 1	1999-02-02
Method of treating cancer using a chimera antibody Grant 5,807,548 - Shitara , et al. September 15, 1	1998-09-15
Polypeptide derivatives of human granulocyte colony stimulating factor Grant 5,795,968 - Kuga , et al. August 18, 1	1998-08-18
Process for producing humanized chimera antibody Grant 5,750,078 - Shitara , et al. May 12, 1	1998-05-12
Polypeptide derivatives of human granulocyte colony stimulating factor Grant 5,714,581 - Kuga , et al. February 3, 1	1998-02-03
DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide Grant 5,681,720 - Kuga , et al. October 28, 1	1997-10-28
Polypeptide derivatives of human granulocyte colony stimulating factor Grant 5,362,853 - Kuga , et al. November 8, 1	1994-11-08
Polypeptide derivatives of human granulocyte colony stimulating factor Grant 5,214,132 - Kuga , et al. May 25, 1	1993-05-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.